Agenus INC (AGEN) — 8-K Filings

8-K Filings (19)

• AGENUS Files 8-K for Undisclosed 'Other Event' on March 24, 2026 — Mar 26, 2026
  AGENUS INC filed an 8-K on March 26, 2026, reporting an "Other Event" that occurred on March 24, 2026. While the specific details of the event are not disclosed
• AGENUS INC Enters Material Definitive Agreement — Oct 9, 2025 Risk: medium
  On October 8, 2025, AGENUS INC. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known as ANTIGENICS
• AGENUS INC. Files 8-K Report — Sep 23, 2025 Risk: low
  On September 17, 2025, AGENUS INC. filed an 8-K report detailing an event under 'Other Events'. The company, formerly known as ANTIGENICS INC /DE/, is incorpora
• AGENUS INC. Files 8-K on Security Holder Vote Matters — Jun 20, 2025 Risk: low
  On June 17, 2025, AGENUS INC. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing, made on June 20, 2025, pert
• AGENUS INC Files 8-K for Material Definitive Agreement — Jun 4, 2025 Risk: medium
  On June 3, 2025, AGENUS INC. (formerly ANTIGENICS INC /DE/) entered into a material definitive agreement. The company, incorporated in Delaware with its princip
• AGENUS INC. Files 8-K on Financials — Mar 11, 2025 Risk: low
  On March 11, 2025, AGENUS INC. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financ
• AGENUS INC. Files 8-K: Material Agreement, Equity Sales — Feb 26, 2025 Risk: medium
  On February 20, 2025, AGENUS INC. entered into a material definitive agreement, creating a direct financial obligation. The company also reported on unregistere
• Agenus Inc. Terminates Material Definitive Agreement — Feb 10, 2025 Risk: medium
  Agenus Inc. reported on February 4, 2025, the termination of a material definitive agreement. The company, formerly known as Antigenics Inc. /DE/, is incorporat
• AGENUS INC. Files 8-K on Exit Costs and Financials — Dec 5, 2024 Risk: medium
  On December 5, 2024, AGENUS INC. filed an 8-K report detailing costs associated with exit or disposal activities. The filing also includes financial statements
• AGENUS INC. Files 8-K: Material Agreement, Financial Obligations, Equity Sales — Nov 27, 2024 Risk: medium
  On November 26, 2024, AGENUS INC. entered into a material definitive agreement. The company also reported the creation of a direct financial obligation and unre
• Agenus Inc. Appoints New CMO, Elects Director — Nov 5, 2024 Risk: medium
  On October 30, 2024, AGENUS INC. announced the appointment of Dr. David E. Johnson as Chief Medical Officer and the election of Ms. Sarah Chen to its Board of D
• Agenus Inc. Reports Director Changes and Financial Updates — Aug 8, 2024 Risk: medium
  On August 7, 2024, AGENUS INC. filed an 8-K report detailing several key events. The company announced the departure of Director Dr. Robert L. S. Van der Laan a
• AGENUS INC Terminates Material Definitive Agreement — Aug 2, 2024 Risk: medium
  On July 30, 2024, AGENUS INC. reported the termination of a material definitive agreement. The filing does not specify the other party involved in the agreement
• Agenus Inc. Appoints New Chief Medical and Scientific Officers — Jun 17, 2024 Risk: medium
  On June 11, 2024, AGENUS INC. announced the appointment of Dr. David E. Johnson as Chief Medical Officer and Dr. Robert J. T. Miller as Chief Scientific Officer
• AGENUS INC. Files 8-K on Security Holder Vote Matters — Jun 14, 2024 Risk: low
  On June 11, 2024, AGENUS INC. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known as ANTIGENICS INC
• AGENUS INC Completes Asset Acquisition/Disposition — May 30, 2024 Risk: medium
  On May 29, 2024, AGENUS INC. (formerly ANTIGENICS INC /DE/) reported the completion of an acquisition or disposition of assets. The company, incorporated in Del
• Agenus Inc. Holds Annual Meeting, Elects Directors — Apr 5, 2024 Risk: low
  On April 3, 2024, Agenus Inc. filed an 8-K report detailing several key events. The company announced the results of its 2024 Annual Meeting of Stockholders, wh
• AGENUS INC. Files 8-K for Regulation FD and Financial Exhibits — Feb 15, 2024 Risk: low
  AGENUS INC. filed an 8-K on February 15, 2024, to report an event under Regulation FD Disclosure and to file Financial Statements and Exhibits. This procedural
• AGENUS Files Routine 8-K on Jan 30; Confirms Nasdaq Listing — Jan 31, 2024
  AGENUS INC. filed an 8-K on January 31, 2024, reporting an 'Other Event' that occurred on January 30, 2024. This filing is a routine update to the SEC, confirmi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX